

Collaborative Working Project Executive Summary

Haematology Capacity and Resource Service Improvement Project

Project Title:

A Collaborative Working Agreement between University Hospitals Leicester (UHL) National Health Service (NHS) and Johnson and Johnson Innovative Medicines UK to work in partnership to address and improve the capacity and resource challenges with the trust haematology service

Partner Organisations:

University Hospitals Leicester NHS Trust, Leicester Royal Infirmary, Infirmary Square,
Leicester LE1 5WW

Johnson and Johnson Innovative Medicines UK, 50-100 Holmers Farm Way, High Wycombe,
Bucks HP12 4EG.

Project Rationale:

The University Hospitals Leicester Haematology Myeloma Service currently faces significant capacity and resource challenges that impact its ability to deliver optimal patient care. Capacity challenges exist in several areas including clinic capacity, Osborne Treatment Centre (OTC) capacity, in-patient capacity and available workforce.

Project Period:

Nov 2025 – Feb 2026.

Project Objectives:

To work collaboratively with UHL to develop solutions to the current and near future resource and capacity challenges including when, how and where treatments are delivered, and will be measured via the KPIs defined in the business case.

- Understand existing pinch-points and identify key drivers for change to utilise existing human and physical resources optimally.
- Identify ways to improve haematology service, patient access to treatment within an appropriate time and reduce burden on the NHS.
- Provide data to enable production of a 'case for change' proposal for solutions

.

Patient Specific:

Based on a successful project and implementation, quicker access to care without delay while having access to outpatient services that optimises treatment and clinical care, while reducing waiting time or rescheduled appointments

Trust Specific:

The Trust will have increased confidence, through scenario planning, that any proposed changes will improve patient flow through the haematology service, patients receiving optimal treatment in appropriate timescale, resulting in high performance vs the National Health Service England (NHSE) Faster Diagnosis Standards.

Johnson and Johnson company specific:

A successful project will be example of a successful collaboration with the NHS.

The project can be used as a case study to be utilised with other NHS organisations, to develop and scale solutions to similar/different NHS challenges.

Contact Details

Johnson and Johnson Innovative Medicines UK: Maria Walsh, Business Unit Director Oncology

University Hospitals Leicester NHS Trust: Caroline Towers: Haematology Project Manager